Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduction or discontinuation of tofacitinib after low disease activity in rheumatoid arthritis
ChiCTR2000039799Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Ruijin Hospital. Primary endpoint: DAS28. Started Jul 2019; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2000039799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039799.